ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
79,781.78
1.67%
S&P 500
5,614.56
-2.70%
Dow Jones
41,911.71
-2.08%
US Dollar vs Yen
147.0455
-0.02%
Brent Oil
69.055
0.02%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Bicara Therapeutics Inc (BCAX) 銘柄情報

Bicara Therapeutics Inc

Bicara Therapeutics Inc (BCAX)

NASDAQ
15.36
-1.19
(-7.19%)
終了 3月11日 5:00AM
15分遅延
15.36
-0.03
(-0.19%)
取引時間後: 5:28AM
15分遅延

個人投資家向けのプロ仕様のツール。

プレミアム

主要統計と詳細

通貨
15.36
買値
15.40
売値
17.50
出来高
455,732
15.11 日の範囲 16.59
11.10 52 週間の範囲 27.95
時価総額
835.824M
前日終値
16.55
始値
16.55
時刻
1
@
15.4
最終取引時間
財務取引量
US$ 7,186,994
VWAP
15.7702
平均取引量 (3 か月)
460,018
発行済株式数
54,415,619
配当利回り
-
PER
-16.11
1 株当たり利益 (EPS)
-0.96
歳入
-
純利益
-51.99M

Bicara Therapeutics Inc について

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor... Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
www.bicara.com
本社
Wilmington, Delaware, USA
設立
-
Bicara Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker BCAX. The last closing price for Bicara Therapeutics was US$16.55. Over the last year, Bicara Therapeutics shares have traded in a share price range of US$ 11.10 to US$ 27.95.

Bicara Therapeutics currently has 54,415,619 shares in issue. The market capitalisation of Bicara Therapeutics is US$900.58 million. Bicara Therapeutics has a price to earnings ratio (PE ratio) of -16.11.

BCAX 最新ニュース

その他のニュース

Form 8-K - Current report
Edgar (US Regulatory)
2025年1月13日
BCAX (-7.19%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
2024年11月13日
BCAX (-7.19%)
期間 †前日比前日比 %始値高値安値平均出来高VWAP
12.0615.488721804513.316.6812.0944762715.09945232CS
43.2927.257663628812.0716.6811.6438463213.6085635CS
12-2.1-12.027491408917.4619.7511.146001814.8511944CS
26-10.89-41.485714285726.2527.9511.141606118.4168105CS
52-10.89-41.485714285726.2527.9511.141606118.4168105CS
156-10.89-41.485714285726.2527.9511.141606118.4168105CS
260-10.89-41.485714285726.2527.9511.141606118.4168105CS

BCAX - Frequently Asked Questions (FAQ)

What is the current Bicara Therapeutics share price?
The current share price of Bicara Therapeutics is US$ 15.36
How many Bicara Therapeutics shares are in issue?
Bicara Therapeutics has 54,415,619 shares in issue
What is the market cap of Bicara Therapeutics?
The market capitalisation of Bicara Therapeutics is USD 900.58M
What is the 1 year trading range for Bicara Therapeutics share price?
Bicara Therapeutics has traded in the range of US$ 11.10 to US$ 27.95 during the past year
What is the PE ratio of Bicara Therapeutics?
The price to earnings ratio of Bicara Therapeutics is -16.11
What is the reporting currency for Bicara Therapeutics?
Bicara Therapeutics reports financial results in USD
What is the latest annual profit for Bicara Therapeutics?
The latest annual profit of Bicara Therapeutics is USD -51.99M
What is the registered address of Bicara Therapeutics?
The registered address for Bicara Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Bicara Therapeutics website address?
The website address for Bicara Therapeutics is www.bicara.com
Which industry sector does Bicara Therapeutics operate in?
Bicara Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
CAPSCapstone Holding Corp
US$ 3.11
(1,144.00%)
74.5k
HMRHeidmar Maritime Holdings Corporation
US$ 2.5599
(69.53%)
37.58M
RDFNRedfin Corporation
US$ 9.76
(67.70%)
92.54M
CKPTCheckpoint Therapeutics Inc
US$ 3.9895
(61.52%)
60.92M
STSSSharps Technology Inc
US$ 0.4399
(48.26%)
591.61M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.78
(-35.54%)
162.75k
PCLAPicoCELA Inc
US$ 0.8499
(-35.12%)
866.61k
CONLGraniteShares ETF Trust GraniteShares
US$ 15.685
(-34.86%)
8.71M
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF
US$ 19.22
(-32.95%)
24.19M
JVACoffee Holdings Co
US$ 6.53
(-31.77%)
988.94k
STSSSharps Technology Inc
US$ 0.4399
(48.26%)
591.61M
NVDANVIDIA Corporation
US$ 106.98
(-5.07%)
364.12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.3701
(-30.86%)
258.67M
TSLATesla Inc
US$ 222.15
(-15.43%)
188.57M
TQQQProShares UltraPro QQQ
US$ 59.81
(-11.27%)
155.18M

議論

フィード全体を表示

最近閲覧した銘柄

NASDAQ
BCAX
Bicara Therapeutics
USOTC
ADYYF
Adyen NV (PK)
BIT
NSCIT1550143
IBRD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す